Literature DB >> 18024526

Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria.

Anna Cabré1, Iolanda Lázaro, Josefa Girona, Josep M Manzanares, Francesc Marimón, Núria Plana, Mercedes Heras, Lluís Masana.   

Abstract

BACKGROUND: Fatty acid-binding protein 4 (FABP4) has been linked to metabolic syndrome development, diabetes, and arteriosclerosis, but the role of FABP4 in target organ damage has not been assessed. We evaluated whether plasma FABP4 is associated with renal dysfunction in type 2 diabetic patients.
METHODS: In 263 individuals (161 type 2 diabetic patients and 102 healthy nondiabetic controls), we analyzed the correlation between FABP4 and creatinine or glomerular filtration index (MDRD-GFR) regarding the presence or absence of microalbuminuria. Patients with severe chronic kidney disease (MDRD-GFR <30 mL/min/1.73 m(2)) or albuminuria were not included.
RESULTS: FABP4 concentrations were higher in diabetic patients with MDRD-GFR <60 mL/min/1.73 m(2) (P <0.001). We observed a significant, direct correlation between FABP4 and creatinine (r = 0.446, P <0.001) and an inverse correlation between FABP4 and MDRD-GFR (r = -0.511, P <0.001) in type 2 diabetic patients, but not in nondiabetic individuals. These correlations were sustained when only those patients without microalbuminuria were analyzed (r = 0.414, P <0.001 and r = -0.510, P <0.001, respectively). Type 2 diabetic patients with FABP4 in the highest tertile compared with those in the lower tertiles had increased adjusted odds ratios for moderate renal dysfunction [7.5 (95%CI 1.8-30.7), P = 0.005 and 15.3 (3.1-76.4), P = 0.001; respectively], independent of microalbuminuria.
CONCLUSIONS: High FABP4 plasma concentrations are associated with high plasma creatinine and low MDRD-GFR in patients with type 2 diabetes even in the absence of microalbuminuria or clinically relevant alterations of creatinine and MDRD-GFR values. FABP4 concentrations should be taken into consideration as an early marker of kidney damage in patients with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18024526     DOI: 10.1373/clinchem.2007.094672

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  21 in total

1.  Relation of plasma fatty acid binding proteins 4 and 5 with the metabolic syndrome, inflammation and coronary calcium in patients with type-2 diabetes mellitus.

Authors:  Roshanak Bagheri; Atif N Qasim; Nehal N Mehta; Karen Terembula; Shiv Kapoor; Seth Braunstein; Mark Schutta; Nayyar Iqbal; Michael Lehrke; Muredach P Reilly
Journal:  Am J Cardiol       Date:  2010-10-15       Impact factor: 2.778

2.  A protein profile of visceral adipose tissues linked to early pathogenesis of type 2 diabetes mellitus.

Authors:  Su-Jin Kim; Sehyun Chae; Hokeun Kim; Dong-Gi Mun; Seunghoon Back; Hye Yeon Choi; Kyong Soo Park; Daehee Hwang; Sung Hee Choi; Sang-Won Lee
Journal:  Mol Cell Proteomics       Date:  2014-01-08       Impact factor: 5.911

3.  Prospective associations of circulating adipocyte fatty acid-binding protein levels with risks of renal outcomes and mortality in type 2 diabetes.

Authors:  Chi Ho Lee; Chloe Y Y Cheung; Yu Cho Woo; David T W Lui; Michele M A Yuen; Carol H Y Fong; Wing Sun Chow; Amin Xu; Karen S L Lam
Journal:  Diabetologia       Date:  2018-09-28       Impact factor: 10.122

4.  Reduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus.

Authors:  Masato Furuhashi; Shinya Hiramitsu; Tomohiro Mita; Takahiro Fuseya; Shutaro Ishimura; Akina Omori; Megumi Matsumoto; Yuki Watanabe; Kyoko Hoshina; Marenao Tanaka; Norihito Moniwa; Hideaki Yoshida; Junnichi Ishii; Tetsuji Miura
Journal:  J Lipid Res       Date:  2015-10-14       Impact factor: 5.922

Review 5.  Small lipid-binding proteins in regulating endothelial and vascular functions: focusing on adipocyte fatty acid binding protein and lipocalin-2.

Authors:  Yu Wang
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

6.  Pre-emptive pharmacological inhibition of fatty acid-binding protein 4 attenuates kidney fibrosis by reprogramming tubular lipid metabolism.

Authors:  Yuting Chen; Yue Dai; Kaixin Song; Yi Huang; Le Zhang; Cuntai Zhang; Qi Yan; Hongyu Gao
Journal:  Cell Death Dis       Date:  2021-06-03       Impact factor: 8.469

7.  Fatty acid-binding protein 4 impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells.

Authors:  Gemma Aragonès; Paula Saavedra; Mercedes Heras; Anna Cabré; Josefa Girona; Lluís Masana
Journal:  Cardiovasc Diabetol       Date:  2012-06-18       Impact factor: 9.951

8.  Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients.

Authors:  Jang Hyun Koh; Young Goo Shin; Soo Min Nam; Mi Young Lee; Choon Hee Chung; Jang Yel Shin
Journal:  Diabetes Care       Date:  2008-10-03       Impact factor: 17.152

9.  FABP4 dynamics in obesity: discrepancies in adipose tissue and liver expression regarding circulating plasma levels.

Authors:  María Isabel Queipo-Ortuño; Xavier Escoté; Victoria Ceperuelo-Mallafré; Lourdes Garrido-Sanchez; Merce Miranda; Mercedes Clemente-Postigo; Rafael Pérez-Pérez; Belen Peral; Fernando Cardona; Jose Manuel Fernández-Real; Francisco J Tinahones; Joan Vendrell
Journal:  PLoS One       Date:  2012-11-05       Impact factor: 3.240

10.  Parallel evolution of circulating FABP4 and NT-proBNP in heart failure patients.

Authors:  Anna Cabré; Pilar Valdovinos; Iolanda Lázaro; Gil Bonet; Alfredo Bardají; Lluís Masana
Journal:  Cardiovasc Diabetol       Date:  2013-05-04       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.